The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.
This article was originally published on MedicalXpress.com
GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds
You may also be interested in:
The Latest
Why stress-related illness is so hard to diagnose, and how a patient-centred playful approach can help
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Read More:
-
Learning French while also developing language skills in one’s mother tongue is no easy task. As a result, allophone children often face learning and communication [...]
-
People who develop multiple sclerosis (MS) as children and grow up in less advantaged neighborhoods may have a larger volume of inflammation and brain tissue [...]
-
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study. The [...]
